标题
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
作者
关键词
-
出版物
Cancers
Volume 12, Issue 10, Pages 2891
出版商
MDPI AG
发表日期
2020-10-16
DOI
10.3390/cancers12102891
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
- (2020) Naveen Pemmaraju et al. BLOOD
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
- (2020) Claire N Harrison et al. BLOOD
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
- (2020) Aaron T. Gerds et al. BLOOD
- Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
- (2020) Aaron T. Gerds et al. BLOOD
- Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study
- (2020) Jean-Jacques Kiladjian et al. BLOOD
- Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
- (2020) Ayalew Tefferi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study
- (2020) Alessandro Rambaldi et al. LEUKEMIA
- Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
- (2020) Jean-Jacques Kiladjian et al. Lancet Haematology
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
- (2020) Heinz Gisslinger et al. Lancet Haematology
- Clinical outcomes of IDH2 ‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib
- (2020) Anand A. Patel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice
- (2020) Yoshinori Ozono et al. LEUKEMIA
- Givinostat: an emerging treatment for polycythemia vera
- (2020) Helen T. Chifotides et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
- (2020) Jessica Petiti et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN
- (2020) Friederike Pastore et al. Cancer Discovery
- Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
- (2020) Andrew T. Kuykendall et al. Cancers
- Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis
- (2019) Naseema Gangat et al. CLINICAL CANCER RESEARCH
- Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms
- (2019) Jen-Chin Wang et al. LEUKEMIA RESEARCH
- Oral Idasanutlin in Patients with Polycythemia Vera
- (2019) John Mascarenhas et al. BLOOD
- Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab
- (2019) Takaaki Maekawa et al. BLOOD
- Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms
- (2019) Cansu Cimen Bozkus et al. Cancer Discovery
- Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- (2019) Abdulraheem Yacoub et al. BLOOD
- Essential Thrombocythemia
- (2019) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- The role of JAK2 inhibitors in MPNs 7 years after approval
- (2018) Francesco Passamonti et al. BLOOD
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
- (2018) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
- (2018) William L. Heaton et al. LEUKEMIA
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- Dysregulated iron metabolism in polycythemia vera: etiology and consequences
- (2018) Yelena Z. Ginzburg et al. LEUKEMIA
- Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis
- (2018) Dongqing Yan et al. CLINICAL CANCER RESEARCH
- Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
- (2018) Valerio De Stefano et al. Blood Cancer Journal
- Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis
- (2017) Laure Gilles et al. JOURNAL OF CLINICAL INVESTIGATION
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis
- (2017) T Maekawa et al. LEUKEMIA
- A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
- (2017) John Mascarenhas et al. LEUKEMIA RESEARCH
- The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature
- (2017) M Zingariello et al. Blood Cancer Journal
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms
- (2016) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
- (2016) Srdan Verstovsek et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera
- (2015) H. Gisslinger et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
- (2015) Qiang Jeremy Wen et al. NATURE MEDICINE
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
- (2015) Gabriela M. Baerlocher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon 2a target JAK2V617F-positive progenitor and stem cells
- (2014) M. Lu et al. BLOOD
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
- (2014) Raajit Rampal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of the TGF- 1 signaling abnormalities in the Gata1low mouse model of myelofibrosis
- (2013) M. Zingariello et al. BLOOD
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
- (2013) G. Barosi et al. BLOOD
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
- (2013) John Mascarenhas et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
- (2013) Guido Finazzi et al. BRITISH JOURNAL OF HAEMATOLOGY
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
- (2013) Michaela Waibel et al. Cell Reports
- Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort
- (2012) P. J. Campbell et al. BLOOD
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients
- (2012) Ariel Amaru Calzada et al. EXPERIMENTAL HEMATOLOGY
- Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
- (2012) Alfonso Quintás-Cardama et al. LEUKEMIA RESEARCH
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- p53 Lesions in Leukemic Transformation
- (2011) Ashot Harutyunyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
- (2011) M Nakatake et al. ONCOGENE
- PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis
- (2010) J.S. Duffield et al. DRUG NEWS & PERSPECTIVES
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
- (2010) A Pardanani et al. LEUKEMIA
- Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
- (2010) Anthony Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia
- (2008) Alessandra Carobbio et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
- (2008) A Quintás-Cardama et al. LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started